ストックスクリーナーアプリを入手
4.18
1.88%
-0.08
前日終値:
$4.26
開ける：
$4.32
24時間の取引高:
671.47K
Relative Volume:
0.99
時価総額：
$340.16M
収益：
$70.14M
当期純損益:
$-76.24M
株価収益率:
-3.7658
EPS:
-1.11
ネットキャッシュフロー:
$-57.06M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
-17.23%
6か月 パフォーマンス:
+39.33%
1年 パフォーマンス:
+46.67%
1日の値動き範囲:
$4.16
$4.46
1週間の範囲:
$4.14
$4.46
52週間の値動き範囲:
$2.56
$6.08
Codexis Inc Stock (CDXS) Company Profile
CDXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
4.18 | 340.16M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-29 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-11-07 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-08-07 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2021-04-12 | 開始されました | Piper Sandler | Overweight |
| 2021-03-01 | 開始されました | Stifel | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-10 | 開始されました | The Benchmark Company | Buy |
| 2019-01-17 | アップグレード | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 開始されました | Stephens | Overweight |
| 2017-10-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-31 | 開始されました | Jefferies | Buy |
| 2017-01-26 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Codexis Inc (CDXS) 最新ニュース
Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Codexis announces the approval of equity grants for new employees - MSN
Codexis to Participate in TD Cowen 45th Annual Health Care Conference - The Manila Times
Jordan Seigel - The Globe and Mail
Exclusive: Codexis Unveils Future Roadmap at Major Healthcare Conference - StockTitan
Baillie Gifford & Co. Sells 119,775 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Synthetic Biology Market Top Companies StudyBota Biosciences - openPR
abrdn plc Reduces Stake in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Strategic Talent Investment: Codexis Awards 66.5K Shares in Employee Equity Package - StockTitan
Codexis, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025 - Nasdaq
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th - GlobeNewswire
Codexis sees $205,481 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Codexis sees $205,481 stock purchase by Opaleye management - MSN
Codexis Earnings Alert: Critical Q4 & Full Year Results Coming February 27 - StockTitan
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Codexis strengthens board with biotech veteran Arthur Levin By Investing.com - Investing.com Nigeria
Codexis, Inc. Appoints Dr. Arthur Levin to Strategic Advisory Board to Enhance Oligonucleotide Expertise - Nasdaq
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - GlobeNewswire
RNA Drug Development Pioneer Joins Codexis: Oligonucleotide Expert Who Created First Approved Antisense Drugs - StockTitan
Codexis (NASDAQ:CDXS) investors are sitting on a loss of 79% if they invested three years ago - Yahoo Finance
Codexis, Inc. (NASDAQ:CDXS) Sees Large Increase in Short Interest - MarketBeat
Taking a Closer Look At Codexis Inc (CDXS) Following Its Recent Trade - Knox Daily
Can you now get a good deal on Codexis Inc’s shares? - US Post News
Biocatalysis Market is Projected to Increase at a CAGR of 5.2% - openPR
Ratio Revelations: Codexis Inc (CDXS)’s Financial Metrics in the Spotlight - The Dwinnex
Institutional investors in Codexis, Inc. (NASDAQ:CDXS) see US$59m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Codexis, Inc. to Host Earnings Call - ACCESS Newswire
Inspire Investing LLC Takes $405,000 Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Has $1.37 Million Stock Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Cantor Fitzgerald Forecasts Codexis FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on Codexis FY2025 Earnings - MarketBeat
Codexis expands board with new director Christos Richards - MSN
Codexis, Inc. (NASDAQ:CDXS) Sees Significant Increase in Short Interest - MarketBeat
Codexis expands board with new director Christos Richards By Investing.com - Investing.com Australia
Tallon Kerry Patrick Purchases New Position in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Barclays PLC Purchases 70,255 Shares of Codexis, Inc. (NASDAQ:CDXS) - Defense World
Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Appoints Christos Richards to Board of Directors - Taiwan News
Codexis appoints new independent director By Investing.com - Investing.com Australia
Codexis, Inc. Appoints Christos Richards to Board of Directors -January 16, 2025 at 04:05 pm EST - Marketscreener.com
Codexis appoints new independent director - Investing.com India
Codexis Strengthens Board with Life Sciences Veteran Christos Richards, Expert in 450+ Executive Placements - StockTitan
Codexis Inc (CDXS) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):